Foghorn Therapeutics (FHTX) Operating Leases (2019 - 2026)

Foghorn Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• In Q1 2026, Operating Leases rose 55.92% year-over-year to $40.1 million; the TTM figure through Mar 2026 stood at $40.1 million (up 55.92% YoY), while the FY2025 annual figure was $40.3 million, up 43.77% from the prior year.
• Operating Leases for Q1 2026 stood at $40.1 million, down from $40.3 million in the prior quarter.
• The five-year high for Operating Leases was $51.5 million in Q4 2022, with the low at $15.8 million in Q3 2025.
• The 5-year median for Operating Leases is $40.1 million (2026), against an average of $37.2 million.
• The sharpest annual moves came in 2025 and 2026: Operating Leases plunged 47.94% in 2025, then soared 55.92% in 2026.
• Foghorn Therapeutics' Operating Leases stood at $51.5 million in 2022, then dropped by 12.49% to $45.1 million in 2023, then tumbled by 37.74% to $28.1 million in 2024, then surged by 43.77% to $40.3 million in 2025, then retreated by 0.54% to $40.1 million in 2026.
• Business Quant data shows FHTX's Operating Leases at $40.1 million in Q1 2026, $40.3 million in Q4 2025, and $15.8 million in Q3 2025.